MindMed reported a net loss of $5.8 million for first 6 months of 2020, has USD $24 million in cash.
MindMed reported a net loss of $5.8 million for first 6 months of 2020, has USD $24 million in cash.
Tryp Therapeutics adds a partner to advance its drug manufacturing capabilities.
MindMed's new President will be expanding the company's R&D footprint in Europe and leading Project Lucy.
A new psychedelics company began trading August 11th.
Mydecine's corporate update notes its "world's first" clinical trials initiative for PTSD.
PharmaDrug takes its first step to begin retail psychedelic sales in the legal market for psychedelic drugs in the Netherlands.
MindMed adds a psychedelics therapy expert to its LSD research program.
LEGAL use of psilocybin in Canada for the first time in nearly 50 years.
Novamind acquires Utah-based Cedar Psychiatry and Cedar Clinical Research for CAD$3.05 million.
More pressure on Ottawa to move forward on legalization of psilocybin.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now